User login
Key clinical point: Aspartate transaminase to platelet ratio index (APRI), international normalized ratio (INR), and albumin-bilirubin (ALBI) grade can help identify patients with liver-dominant metastatic colorectal cancer (mCRC) who may benefit from transarterial radioembolization (TARE) with 90Y resin microspheres.
Major finding: APRI >0.40 independently predicted worse overall survival (OS; hazard ratio [HR] 2.25; P < .0001), progression-free survival (PFS; HR 1.42; P = .0416), and hepatic PFS (HR 1.50; P = .0207). The other independent predictors for worse OS and hepatic PFS were an INR <1 (HR 1.66; P = .0091) and ALBI grade 3 (HR 5.29; P = .0075), respectively.
Study details: This study evaluated 237 patients with liver-dominant mCRC from the prospective observational CIRSE Registry for SIR-Spheres Therapy (CIRT) study scheduled to receive TARE with 90Y resin microspheres.
Disclosures: The CIRT study was funded by SIRTEX Medical Europe GmbH (Bonn, Germany). Some authors declared receiving grants, consulting fees, honoraria, or lecture and travel support from or serving on data safety monitoring or advisory boards for various sources, including SIRTEX.
Source: Schaefer N et al, on behalf of the CIRT Principal Investigators. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: Results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022 (Sep 19). Doi: 10.1016/j.clcc.2022.09.002
Key clinical point: Aspartate transaminase to platelet ratio index (APRI), international normalized ratio (INR), and albumin-bilirubin (ALBI) grade can help identify patients with liver-dominant metastatic colorectal cancer (mCRC) who may benefit from transarterial radioembolization (TARE) with 90Y resin microspheres.
Major finding: APRI >0.40 independently predicted worse overall survival (OS; hazard ratio [HR] 2.25; P < .0001), progression-free survival (PFS; HR 1.42; P = .0416), and hepatic PFS (HR 1.50; P = .0207). The other independent predictors for worse OS and hepatic PFS were an INR <1 (HR 1.66; P = .0091) and ALBI grade 3 (HR 5.29; P = .0075), respectively.
Study details: This study evaluated 237 patients with liver-dominant mCRC from the prospective observational CIRSE Registry for SIR-Spheres Therapy (CIRT) study scheduled to receive TARE with 90Y resin microspheres.
Disclosures: The CIRT study was funded by SIRTEX Medical Europe GmbH (Bonn, Germany). Some authors declared receiving grants, consulting fees, honoraria, or lecture and travel support from or serving on data safety monitoring or advisory boards for various sources, including SIRTEX.
Source: Schaefer N et al, on behalf of the CIRT Principal Investigators. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: Results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022 (Sep 19). Doi: 10.1016/j.clcc.2022.09.002
Key clinical point: Aspartate transaminase to platelet ratio index (APRI), international normalized ratio (INR), and albumin-bilirubin (ALBI) grade can help identify patients with liver-dominant metastatic colorectal cancer (mCRC) who may benefit from transarterial radioembolization (TARE) with 90Y resin microspheres.
Major finding: APRI >0.40 independently predicted worse overall survival (OS; hazard ratio [HR] 2.25; P < .0001), progression-free survival (PFS; HR 1.42; P = .0416), and hepatic PFS (HR 1.50; P = .0207). The other independent predictors for worse OS and hepatic PFS were an INR <1 (HR 1.66; P = .0091) and ALBI grade 3 (HR 5.29; P = .0075), respectively.
Study details: This study evaluated 237 patients with liver-dominant mCRC from the prospective observational CIRSE Registry for SIR-Spheres Therapy (CIRT) study scheduled to receive TARE with 90Y resin microspheres.
Disclosures: The CIRT study was funded by SIRTEX Medical Europe GmbH (Bonn, Germany). Some authors declared receiving grants, consulting fees, honoraria, or lecture and travel support from or serving on data safety monitoring or advisory boards for various sources, including SIRTEX.
Source: Schaefer N et al, on behalf of the CIRT Principal Investigators. Prognostic factors for effectiveness outcomes after transarterial radioembolization in metastatic colorectal cancer: Results from the multicentre observational study CIRT. Clin Colorectal Cancer. 2022 (Sep 19). Doi: 10.1016/j.clcc.2022.09.002